Predicting treatment response prior to neoadjuvant therapy was assessed in the ARNEO trial by Devos et al., who demonstrated that PTEN loss in the initial prostate biopsy was associated with significantly less MRD (p = 0.002) and a higher residual cancer burden (RCB, p < 0.001) in the RP specimen compared to those without PTEN loss [18]. This evidence concerns the gene PTEN and cancer.